Related Experiment Videos
[Clinical study of S-6437 in pediatrics (author's transl)]
Insights
This study evaluated sustained-release cephalexin in pediatric patients, demonstrating an 87.9% effectiveness rate for common bacterial infections. The antibiotic showed a favorable safety profile with minimal side effects observed.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Infectious Diseases
Context:
- Bacterial infections in children require effective and safe treatment options.
- Cephalexin is a commonly prescribed antibiotic for various infections.
- Sustained-release formulations aim to improve patient compliance and therapeutic outcomes.
Purpose:
- To assess the efficacy and safety of a sustained-release cephalexin formulation (S-6437) in pediatric patients.
- To determine appropriate pediatric dosing for sustained-release cephalexin based on body weight.
- To evaluate the clinical response and adverse events associated with this new formulation.
Summary:
- A clinical study involved 35 pediatric patients with infections like scarlet fever, pharyngitis, and tonsillitis.
- Patients received sustained-release cephalexin (200 mg/g granules) with weight-based dosing.
- An overall effectiveness rate of 87.9% was observed, with 11 "very good" and 18 "good" responses.
- Adverse events were limited to mild cheilitis and vomiting in two patients, with two others experiencing administration difficulties.
Impact:
- Sustained-release cephalexin presents a potentially effective and well-tolerated treatment option for pediatric bacterial infections.
- The study provides valuable data on dosing and efficacy for this formulation in a young population.
- Further research may explore long-term outcomes and broader applications of sustained-release cephalexin in pediatric care.
Abstract:
Clinical study of sustained release cephalexin (granules, 200 mg/g, S-6437) was conducted in pediatric patients as follows: 1. For infants under 20 kg of body weight, 25 approximately 50 mg/kg/day of this preparation (or 50 approximately 100 mg/kg/day for severe diseases) were given in two divided doses, and for infants over 20 kg, 1 g (or 2 g for severe diseases) were administered at two divided doses. 2. Patients treated with this preparation were 27 cases with scarlet fever, 3 with acute pharyngitis, 2 with acute tonsillitis, 1 with acute laryngitis, 1 with acute cystitis and 1 with acute enteritis. 3. Out of the 35 patients, 11 showed "very good" response to this preparation, 18 "good", 3 "fair", 1 "poor", and 2 "unknown" indicating 87.9% of effectiveness. 4. Side effects of cheilitis in one patient and vomiting in 1 were observed, and other 2 patients had difficulty in taking this preparation. No other side effects were found.